Why triglycerides need to be aggressively managed: A guide for physicians

Cardiovascular Reviews and Reports

Volumn 24, Issue 10, 2003, Pages 520-526

  Miller, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIET THERAPY; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIPOPROTEIN METABOLISM; MEDICAL PRACTICE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

EID: 0141992979     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol. 1999;83:3F-12F.
2. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study. Can J Cardiol. 1988;4(suppl A):5A-10A.
3. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
4. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.
5. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
6. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
7. Tanne D, Koren-Morag N, Graff E, et al., for the BIP Study Group. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation. 2001;104:2892-2897.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
9. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81(suppl 4A):18B-25B.
10. Tahnud PJ. Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr Atheroscler Rep. 2001;3:191-199.
11. Busch CP, Hegele RA. Variation of candidate genes in triglyceride metabolism. J Cardiovasc Risk. 2000;7:309-315.
12. Kwiterovich PO Jr. Lipoprotein heterogeneity: diagnostic and therapeutic implications. Am J Cardiol. 2002;90:1i-10i.
13. Grundy SM. Consensus statement: role of therapy with "statins" in patients with hypertriglyceridemia. Am J Cardiol. 1998;81(suppl 4A):1B-6B.
14. Frick MH, Flo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
15. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-27.
16. Manninen V, Tenkanen L, Koskinen R et al. Joint effects of serum triglyceride and LDL cholesterol and HDL, cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-46.
17. Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J. 2000;140:232-240.
18. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus 'usual' care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220-228.
19. Hirsch GA, Vaid N, Blumenthal RS. The significance of measuring non-HDL-cholesterol. Prev Cardiol. 2002;5:156-159.
20. Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor. Clin Cardiol. 1999;22(6 suppl):II1-II6.
21. Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol. 1998;31:1252-1257.
22. Miller M, Zhan M, Georgopoulos A. Effect of desirable fasting triglycerides on the postprandial response to dietary fat. J Med Invest. 2003;51:50-55.
23. Kris-Etherton PM, Harris WS, Appel LJ, for the American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-2757.
24. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
25. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation. 1992;86:1-11.
26. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-69B.
27. Ballantyne CM, Andrews TC, Hsia JA, et al., for the ACCESS Study Group. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88:265-269.
28. Stein DT, Devaraj S, Balis D, et al. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2001;21:2026-2031.
29. Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002;163:287-296.
30. Guerin M, Egger P, Le Goff W, et al. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIB hyperlipidemia. J Clin Edocrinol Metab. 2002;87:4991-5000.
31. Hunninghake DB. Pharmacologic management of triglycerides. Clin Cardiol. 1999;22(6 suppl):II44-II48.
32. Pontrelli L, Parris W, Adeli K, et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases the low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 2002;51:334-342.
33. Miller M, Dolinar C, Cromwell W, et al. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol. 2001;87:232-234.
34. Forster LF, Stewart G, Bedford D, et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis. 2002;164:129-145.
35. Rubins HB, Robins S, Collins D, et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
36. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 2002;128:159-168.
37. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
38. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
39. Niaspan Extended-Release Tablets [package insert]. Miami, FL: Kos Pharmaceuticals, Inc.; 1999.
40. Harris WS. N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243-252.
41. GISSI-Prevenzione Investigators. (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-455.
42. Schaefer FJ, McNamara JR, Shah PK. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care. 2002;25:989-994.
43. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. Diabetes Care. 2001;24:1335-1341.
44. Tikkanen MJ, Laakso M, Ilmonen M, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM: a multicenter comparison study. Diabetes Care. 1998;21:477-481.
45. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet. 2001;357:905-910.
46. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med. 2002;162:1568-1576.
47. Gilman AG, Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill Professional; 2001.